NPPA fixes retail prices for nine newly introduced drug formulations
NPPA fixes retail prices for nine newly introduced drug formulations
Based on notification dated: Sep 15th, 2025,
Released on: Sep 16th, 2025
National Pharmaceutical Pricing Authority (NPPA) has announced the retail prices for nine newly introduced drug formulations, comprising three anti-inflammatory fixed-dose combinations (FDCs) and six antidiabetic medications. The pricing decision was finalized during the NPPA’s 137th Authority meeting held on September 15, 2025.
NPPA Clarifies Pricing Rules for New Drugs under DPCO 2013 & NLEM
These formulations fall under the category of 'New Drugs' as defined in Paragraph 2(u) of the Drugs (Prices Control) Order, 2013. The NPPA clarified that the prices were calculated following the norms specified in Paragraphs 5 and 15 of the DPCO, 2013, based on applications submitted by pharmaceutical companies. Manufacturers may add GST to the retail price, if applicable.
Click here to know more and access the official guidance document
Note:
Cases related to Pharmaceuticals are highly technical and knowledge-driven. If you're searching for a drugs and cosmetics lawyer in India, a pharmaceutical lawyer, Mace Corporate Associates is the perfect place. If you are searching for a DPCO Lawyer for overcharging cases or DPCO Compliance, Mace can assist you well.
May it be a clinical trial Lawyer or a Medical device lawyer, Mace can be of great and perfect match for Pharmaceutical litigation. Mace has an accomplished track record for Not of Standard Quality Cases, Licensing Cases etc.
Want to know more?
Our team will answer all your questions. we ensure a quick response.
(011)-46113619